🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Financials Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (broadly including banks, funds, REITs, and related sectors), overarching themes reveal robust M&A/divestiture activity (10+ deals like CWBC merger, CHS $459M sale, Duke $2.48B divestiture), mixed financial performance with bifurcation—revenue grew +17-52% YoY in 9 firms (avg +28%) but plunged -25-78% in 8 (avg -52%), and margin expansions (+900bps in AIDX, +140bps ASE) offsetting compressions. Capital allocation favors returns ($766M WY cash to SH, Cal-Maine $24.3M buyback/$0.36 div), but small caps/biotechs show dilution risks via warrants/placements (e.g., LABT $7.5M pref, Cadrenal inducement). Forward-looking catalysts include growth targets (WY $1.5B EBITDA by 2030, Lamb Weston raised FY26 guidance $6.45-6.55B sales), fund conversions (TCW Jun 2026), and AGMs (WY May 15). Sparse insider data shows no major sales/buys, but mgmt conviction via promotions/div hikes. Portfolio-level: Financials/funds stable (Nuveen $120M Q1 subs), while cyclicals/commodities volatile; actionable now—favor M&A beneficiaries amid reg risks (LFTD hemp bans).

32 high priority 18 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the S&P 500 Consumer Staples stream (April 1, 2026), dominant themes include proxy season acceleration with 20+ DEF 14A/DEFA14A filings for May 2026 annual meetings emphasizing director elections, say-on-pay, and auditor ratifications, alongside mixed Q3/FY2025 results showing organic sales resilience (e.g., Conagra +2.4% organic vs -1.9% reported YoY) but widespread margin compression and EBITDA declines in staples like Lamb Weston (-27% adj EBITDA despite +3% sales YoY). M&A activity surges with Keurig Dr Pepper's 96.22% acquisition of JDE Peet’s (EUR 9.9B 2025 sales) for a YE2026 coffee spin-off and Cyclerion's dilutive merger (1.5% ownership retention). Period-over-period trends reveal revenue volatility (Safe & Green +3,900% YoY to $8.2M but loss widened to $16M; Rocky Mountains -50.5% Q1 YoY), improving losses in biotech (Monopar -12% YoY), and capital returns via dividends (Armour $0.24/share, Lamb $0.38) and buybacks (IPG $50M, DFIN $172M record). Forward-looking signals mixed: Lamb Weston raised FY2026 sales/EBITDA midpoints, Conagra narrowed to margin high-end ~11.0-11.5%, with catalysts like BioXcel FDA PDUFA Nov 14, 2026. Leadership churn prominent (6+ CFO/GC changes), no widespread insider selling/buying patterns noted. Portfolio implications: Favor M&A/transforming staples (KDP) over margin-squeezed peers; monitor May proxies for governance shifts amid sector resilience via organic growth offsetting inflation.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 01, 2026

Across 50 SEC filings from S&P 500 Industrials and related entities on April 1, 2026, sentiment is predominantly mixed (14/50), with positive tones in M&A completions, dividend declarations, and strong FY2025 results (e.g., L3Harris $21.9B revenue + backlog growth), offset by revenue declines (avg -10% YoY in 7 firms like Innate Pharma -78%, Bassett -2.2%) and widening losses (e.g., Safe & Green net loss +79% to $16M). Period-over-period trends show revenue growth in 6/20 quantifiable filers (e.g., URBN +11.1%, Enphase $1.5B), margin expansions in outperformers (L3Harris + to 15.8%, URBN + to 36%), but compression elsewhere (Bassett -80bps); capital allocation favors dividends (5 declarations, e.g., Global Net Lease $0.19/share) and buybacks (URBN $177M, IPG $50M). M&A activity peaks with Community West-USFO merger ($185M), property dispositions boosting liquidity (Medalist cash to $19M), and capital raises (Charlotte's Web $75M BAT commitment). Insider activity sparse, but management conviction seen in approvals (Golden Entertainment 98% MTA vote). Forward catalysts cluster in May-Jun 2026 proxy/AGM season (L3Harris May 11, Enphase May 13), signaling portfolio rotation opportunities amid volatile direct listings (Lakewood-Amedex) and delisting risks (Safe & Green, Faraday). Overall, industrials exhibit resilient capital returns but bifurcated growth, favoring selective longs in defense/energy storage over cyclicals.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 01, 2026

The USA S&P 500 Energy stream reflects a very quiet session dominated by routine proxy filings from ONEOK and SunCoke Energy, with neutral sentiment across three filings (materiality 4-6/10) focusing on standard governance matters like director elections, auditor ratifications, and say-on-pay votes ahead of May 2026 virtual AGMs. Hall Chadwick Acquisition Corp's 8-K stands out as the most significant development (positive sentiment, 8/10 materiality), announcing a non-binding LOI with REEcycle Holdings for a potential de-SPAC transaction, signaling early M&A activity in energy-adjacent recycling. No explicit period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity disclosed across filings, indicating stable but unremarkable operational momentum; board metrics at SunCoke show consistent 2025 activity with 10 board meetings and 15 committee meetings at >75% attendance versus typical sector norms of 8-12 meetings. Forward-looking elements highlight auditor engagements through Dec 31, 2026, and AGM catalysts on May 14-20, 2026. Portfolio-level themes include strong board independence (SunCoke: 5/6 independent directors) and governance continuity, implying low near-term volatility but limited alpha catalysts beyond Hall Chadwick's deal potential. Overall implications: defensive positioning for Energy sector amid proxy season, with watch for shareholder vote outcomes.

3 high priority 1 medium 4 total filings
· daily

US Material Events SEC 8-K Filings — April 01, 2026

Across 50 SEC filings from April 1, 2026, dominant themes include a surge in M&A completions and amendments (12/50 filings, e.g., CWBC-UBFO merger, Ondas-World View acquisition), executive transitions (15+ CFO/CEO/Director changes, mostly positive appointments), and credit facility expansions/amendments (10+ cases boosting liquidity, e.g., Cousins $1.2B revolver, Enova multiple increases). Period-over-period pro forma trends show mixed results: divestitures drove revenue declines averaging ~30-55% YoY (Duke -15%, Medalist -55%, CHS -$327M) but gains/debt reductions (Duke net income +102% to $887M, CHS +$138M after-tax gain); no broad margin compression but operational income drops in divested units. Forward-looking catalysts cluster in Q2-Q3 2026 (merger closings, systems conversions, JDE delisting Apr 30). Portfolio-level patterns indicate financial sector consolidation (banks/REITs), AI/defense tuck-ins, and improved capital access amid neutral-to-positive sentiment (65% positive/neutral). Critical implications: enhanced liquidity supports growth, but dilution risks in biotech/SPACs and revenue gaps from sales signal monitoring for earnings impacts.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 01, 2026

Across 50 SEC filings from Dow Jones 30-related entities and peers on April 1, 2026, overarching themes include robust M&A activity (e.g., Community West merger completion, SharonAI $1.25BN deal, Ondas acquisition), mixed 10-K results with strong revenue growth (avg +100% YoY in growth outliers like Amaze Holdings +558%, Charlie's +169%) but persistent net losses and impairments, and proxy season ramp-up with 15+ AGMs in May 2026. Period-over-period trends show revenue expansion in 12/20 10-Ks (e.g., URBAN +11.1% to $6.2B, ASIAFIN +51.6%), but margin compression or widened losses in 14 cases (e.g., NIKE gross profit -3.1% YoY Q3), alongside positive capital returns like Lamb Weston $0.38 dividend and Las Vegas Sands $2.94B buybacks/dividends. Critical developments feature SPAC mergers progressing (Brag House extension to May 29), Nasdaq delisting risks (Brand House), and forward guidance raises (Lamb Weston FY2026 sales $6.45-6.55B). Portfolio-level patterns indicate sector rotation toward AI/tech (SharonAI, BSTR Bitcoin treasury) amid blue-chip stability, with 8 positive sentiments on deals vs 18 mixed on financials, signaling selective opportunities in consolidations despite operational pressures.

30 high priority 20 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 01, 2026

Across 50 SEC filings dated April 1, 2026, dominant themes include elevated M&A and SPAC activity (10+ filings: Haymaker, Community West, Cyclerion, Golden Entertainment), mixed financial results with 12 companies showing YoY revenue growth averaging +45% (e.g., Charlie's +169%, RH +8%) offset by sharp declines in 8 firms averaging -38% (Cal-Maine -53%, OLB -32%), and margin expansions in select industrials/biotechs (ASE gross +140 bps to 17.7%) amid compressions elsewhere. Proxy statements (Circle, Weyerhaeuser) highlight positive 2025 recaps and growth strategies, while biotechs/pharmas (Lakewood-Amedex, IceCure, Adaptin) pursue listings/raises amid losses. Capital returns strong in resources (Weyerhaeuser $766M, +5% dividend) and buybacks (News Corp $1B program), but impairments and regulatory risks (LFTD $23M goodwill) pressure consumer/health sectors. Portfolio-level: 60% mixed sentiment, with M&A driving near-term catalysts but cyclical downturns in ag/food/eggs signaling caution. Implications: Favor M&A plays and dividend growers; monitor May shareholder votes for comp approvals/guidance.

33 high priority 17 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 01, 2026

The 50 filings reveal polarized performance in the Consumer Discretionary stream, with standout revenue growth in apparel/retail like URBN (+11.1% YoY sales to $6.2B, op income +27.8%) and niche players (ASIAFIN +51.6% YoY, Safe & Green x40 to $8.2M) contrasting sharp declines in food/retail (Cal-Maine Q3 sales -53% YoY, net income -90.1%; Bassett -2.2% sales, op income -52.9%) and EVs (SHF -50% revenue). Margin trends mixed: expansions in URBN (gross to 36.0%) but compressions averaging -100bps across 5 reporters (Bassett -80bps, Nike gross -3.1% Q3 YoY). Capital allocation emphasizes returns with buybacks (URBN $177M/3.7M shares, Cal-Maine $24.3M) and dividends (multiple payable Apr-May 2026). Forward catalysts cluster Q2: earnings (O'Reilly, Blue Owl May), AGMs (URBN June 3, Cinemark May 14), M&A closes (Cal-Maine Creighton). Regulatory risks (LFTD hemp bans threatening 52% sales by Nov 2026) and listing issues (Faraday Nasdaq bid <1) heighten volatility. Portfolio implication: favor resilient retail growth plays amid cyclical pressures.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (with broader US equity context), dominant themes include a wave of proxy statements (DEF 14A/DEFA14A) for May 2026 annual meetings signaling governance focus amid neutral sentiment; aggressive M&A in regional banks adding $1B+ in assets (e.g., Fulton, CVB, Associated Banc); and mixed biotech performance with 7/12 healthcare firms reporting widened YoY net losses (avg +70%) from R&D ramps (e.g., Forte +95% expenses) offset by cash infusions and pipeline catalysts. Period-over-period trends show healthcare revenue volatility (Interpace Q4 -26% YoY GAAP but thyroid +14%; iSpecimen tissue rev -54% mix share) contrasted by strong bank deposit/loan growth post-mergers; capital allocation leans toward accretive deals over buybacks (News Corp $1B program outlier). Insider activity limited to routine tax-related sales (CCEP PDMRs net zero accumulation). Critical developments: Biotech catalysts like TuHURA Phase 3 enrollment mid-2027 and Forte 2026 readouts; bank expansions positioning for organic growth; implications favor monitoring healthcare turnarounds amid high burn rates while bank M&A offers stability in uncertain markets.

26 high priority 24 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 01, 2026

Across 50 DEF 14A proxy statements, US companies showcase resilient 2025 performance with strong capital returns totaling billions (e.g., Las Vegas Sands $2.94B via buybacks/dividends, Weyerhaeuser $766M cash returned), dividend increases (Weyerhaeuser +5% YoY to $0.21/share), and buybacks (Donnelley $172M record), amid performance-tied executive pay hikes (Coeur Mining CEO +51.5% YoY to $6.65M on 133% AIP payout). Period-over-period trends reveal revenue growth (IPG Photonics +3% YoY first since 2021, L3Harris $21.9B), EBITDA records (Sands $5.23B, Weyerhaeuser ~$1.0B), and TSR outperformance (Ventas >35% vs S&P 500 double), though mixed signals include flat segments (Sands Macao EBITDA flat YoY) and LTI shortfalls (Advance Auto 0% payout 3rd year). Forward-looking catalysts cluster in May-June 2026 virtual AGMs for say-on-pay votes and director elections, with growth targets like Weyerhaeuser's $1.5B incremental EBITDA by 2030 and Sands' $8B MBS expansion. No widespread insider selling or pledges noted (e.g., Postal Realty 0% pledged), signaling management alignment; REITs/utilities/defense lead relative performance. Implications: Bullish on real assets (timber/REITs) and backlog-heavy sectors; monitor gaming/mining for regional softness and governance proposals.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 01, 2026

The IPO Pipeline stream features two key SEC filings: Expro Ltd's S-4 for redomiciliation to Cayman Islands with NYSE listing under XPRO, signaling structural optimization for growth, and TRIC Global's S-1 for an imminent IPO as a nascent Connect platform developer. Expro exhibits strong positive sentiment (9/10 materiality) with 10.5% holder Oak Hill Advisors committing to vote in favor, no operational changes, and minimal 1% dilution risk from withdrawals, positioning it for enhanced liquidity and flexibility. TRIC, incorporated December 2025, reports neutral sentiment (9/10 materiality) with zero revenue, expenses, compensation, facilities, patents, or governance structures for FY ended Dec 31, 2025, highlighting early-stage risks. No YoY/QoQ financial trends available across filings, but TRIC's $0 metrics vs Expro's established structure underscore a bifurcation in pipeline maturity. Portfolio-level theme: 1/2 filings show positive restructuring catalysts amid governance voids in new entrants, implying selective opportunities in relistings over pure IPOs. Market implications include near-term NYSE catalyst for Expro and prolonged scrutiny for TRIC's S-1 effectiveness.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — April 01, 2026

Across 50 filings on April 1, 2026, critical market events reveal robust M&A and divestiture activity (e.g., CWBC-UBFO merger, CHS hospital sale, Duke Energy asset sale) boosting cash positions and gains, contrasted by liquidity strains in Indian firms via encumbrances (e.g., IndusInd, Embassy) and defaults (Patspin ₹24.37 Cr). Period-over-period trends show polarized performance: revenue growth in semis (ASE +8.4% YoY), foods (ITC Sproutlife +85.2% YoY), but sharp declines in ag/food (Cal-Maine -53% YoY net sales Q1, OLB -32% YoY) and crypto trusts (Osprey net assets -24.4% YoY). SPAC restructurings (Haymaker multiple positives) and biopharma listings (LABT direct listing) signal bullish de-SPAC momentum, while impairments and losses dominate small caps (Amaze -wide net loss, LFTD massive goodwill write-offs). Capital returns strong in timber (Weyerhaeuser $766M), but high debt/encumbrances flag risks; overall sentiment mixed with 14 positive, 16 mixed, 8 negative. Portfolio implications: overweight completed M&A for cash boosts, underweight distressed Indian industrials/banks; watch SPACs and aviation amid geo-risks.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — April 01, 2026

The intelligence stream on USA Trading Suspensions reveals a single high-materiality (9/10) event for The Brand House Collective, Inc. (TBHC), flagged with a Nasdaq deficiency notice on March 26, 2026, for MVPHS below $15M for 30 consecutive business days, breaching Listing Rule 5450(b)(3)(C). No immediate trading halt occurred, but delisting risk looms if compliance isn't regained by September 22, 2026, via $15M MVPHS for 10 consecutive days. A pending merger with Bed Bath & Beyond, Inc. (announced November 24, 2025) is expected to close beforehand, triggering voluntary delisting as TBHC becomes a wholly owned subsidiary, with the parent's common stock remaining NYSE-listed. No period-over-period financial trends, insider activity, capital allocation details, or operational metrics were enriched in the filing, limiting quantitative comparisons, but negative sentiment dominates due to compliance uncertainty. This isolated case underscores small-cap liquidity vulnerabilities on Nasdaq, with merger as a potential resolution catalyst. Investors face heightened volatility risks ahead of the compliance deadline.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 01, 2026

Across 44 8-K filings in the USA Corporate Distress & Bankruptcy stream (28 new), the dominant theme is proactive liquidity enhancement via 22+ credit facility amendments, extensions, or increases (e.g., Primo Brands refin $3.09B, American Assets Trust rev to $500M), signaling lender confidence and low imminent distress despite the stream focus. No outright bankruptcies or going concern warnings; mild distress in TBHC Nasdaq MVPHS deficiency (delist risk Sept 2026) and Westwater's SK On contract termination. Positive capital allocation trends include consistent dividends (Armour $0.24/share Apr, Nuveen $0.170/share Apr 28) and equity raises/mergers (SharonAI $1.25BN TCV, Cyclerion/Korsana). Period trends sparse but highlight modest fund returns (Nuveen Churchill Class I: 0.21% 1-mo, 0.74% YTD as of Feb 2026) vs stable REIT payouts; no broad YoY/QoQ declines. Forward catalysts cluster in Q2-Q3 2026 (merger closes, production ramps). Portfolio implication: Sector resilient, favoring liquidity plays over distress shorts; monitor delist/termination outliers for alpha.

44 high priority 44 total filings
· daily

US Executive Officer Management Changes SEC — April 01, 2026

Across 34 filings in the USA Executive & Director Changes stream (22 new since last brief), the dominant theme is aggressive leadership refreshes with 18 new appointments (8 CFOs/COOs, 10+ directors) versus 9 departures/resignations, emphasizing experienced hires in finance, tech/AI, and biopharma to drive 2026 growth amid M&A integrations and strategic pivots. Positive sentiment prevails in 16/34 (47%) filings, driven by hires like Zymeworks' Royalty Pharma CFO and Nexscient's AI CTO acquisition, while neutral/mixed in departures with reaffirmed FY2026 guidance (CVGI, Avantor, Clover). No broad period-over-period financial declines noted, but forward-looking highlights include Bunge's $Viterra synergy PBRSUs (2026-2028), Predictive Oncology's $7.5M 2026 run-rate income est from $12M AI GPU deals, and Associated Banc's post-merger 2025 record net income. Capital allocation trends favor equity incentives (e.g., Consensus Cloud $700K+ grants vesting on 2026 metrics, EPAM $3M RSU retention), signaling alignment without dividends/buybacks mentioned. Portfolio-level pattern: Small/mid-cap turnover (avg materiality 7/10) with interim stability suggests operational continuity, but NovaBay's pharma-to-Stablecoin pivot (materiality 9/10) flags high-risk reinvention. Implications: Bullish for growth-oriented firms, watch CFO interims for execution risks in H1 2026.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 01, 2026

Across 34 filings from April 1, 2026, a surge in C-suite leadership changes dominates, with 9 CFO-related shifts (5 appointments, 3 departures/terminations, 1 interim promotion) signaling high turnover amid growth strategies in tech, biotech, and finance sectors. Board appointments (14 positive/neutral additions) emphasize expertise in finance, M&A, and AI, often tied to post-acquisition integrations (e.g., Bunge Viterra synergies 2026-2028, Associated Banc-Corp merger Q3 2026 conversion). Positive sentiment prevails in 16/34 filings (47%), driven by hires like Royalty Pharma alum at Zymeworks and Goldman Sachs vet at Elauwit, while neutral/mixed in resignations and equity grants. No broad YoY revenue declines noted, but reaffirmations of FY2026 guidance in 5 companies (CVGI, Avantor, Clover Health) despite changes indicate operational stability; equity incentives average $300K-$3M grants vesting 3-4 years on performance metrics. Portfolio trend: 65% of changes post-2025 M&A/IPO, with compensation up 20-50% YoY for new execs (e.g., Consensus CFO base $345K). Implications: Bullish for strategic refreshes in AI/biotech, caution on CFO churn potentially disrupting Q2 2026 reporting.

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — April 01, 2026

A surge in US M&A and takeover activity dominates the 30 filings, with 12 bank/regional financial mergers completing on April 1, 2026 (e.g., CWBC/UBFO at $185.5M, SPFI/BOH adding $744M assets, FirstSun/First Foundation creating $20.4B asset entity), signaling aggressive consolidation in regional banking amid $5B-$34B combined asset footprints. SPAC ecosystem thrives with 6 IPO pricings/LOIs (e.g., Future Money $100M, QDRO $200M) and preparatory restructurings, while divestitures (8 cases) boost pro forma cash (e.g., Duke $2.48B proceeds, CHS $459M gain) but compress revenues (avg -15% YoY pro forma across 7 with data). Spin-offs like Versigent (Aptiv carve-out, $8.8B rev +3% YoY, EBITDA to expand 200bps over 3yrs) and mixed JV/deals (Lands' End $300M IP swap) highlight portfolio optimization. Portfolio-level trends show pro forma net income gains from one-time sale gains (avg +100% in 5 cases) offsetting op rev declines (-1.8% to -55%), with positive sentiment in 70% of filings. Implications: Regional banks gain scale for efficiency; watch summer 2026 systems conversions as catalysts; SPACs signal dry powder for de-SPAC waves.

30 high priority 30 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 01, 2026

Across 50 overnight SEC filings (March 31-April 1, 2026), mixed sentiment prevails with 18 mixed, 9 positive, 8 negative, and rest neutral, driven by volatile period-over-period trends: revenue declines averaging -30% YoY in agribusiness (e.g., Cal-Maine -53%, OLB Group -32%) offset by growth in consumer/luxury (RH +8.1%, Charlie's +169%) and select industrials (ASE Tech +8.4%). SPAC/de-SPAC activity surges with 7 filings (Haymaker, Golden Entertainment approvals, Brag House amendments), signaling merger momentum amid $167M+ PIPE raises. Capital allocation leans shareholder-friendly: dividends declared (Weyerhaeuser +5% to $0.21, Cal-Maine $0.36, Global Net Lease $0.19), buybacks (News Corp $1B program, Cal-Maine $24.3M), but cash burn persists in biotechs/small caps. Outliers include RH's net income +72% YoY and Maui Land's leasing +33% YoY, while impairments/goodwill write-offs hit 8 firms (e.g., LFTD $23M). Forward catalysts cluster in April-May (meetings, dividends, acquisitions), implying pre-market volatility in SPACs, foods, and REITs. Portfolio implication: Rotate from cyclical agri declines to SPAC completions and dividend growers for alpha.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 31, 2026

Across 29 diverse SEC filings (primarily small/mid-cap non-tech firms despite S&P 500 Tech stream focus, with Snowflake and SEALSQ as key tech outliers), overarching themes include volatile revenue growth (12/29 firms reported YoY revenue increases averaging +200% in winners like Adia Nutrition +10,885%, but 8/29 declines averaging -25% like Planet Green -35%), persistent net losses widening in 14/29 (avg +50% YoY), offset by positive capital allocation in 5/29 (buybacks, dividends). Margin trends mixed: compression in 7/29 (e.g., BlockchAIn 19% vs prior 37%), improvements in cinema/real estate niches. Critical developments: M&A/mergers (Richmond Mutual, Reading acquisitions), biotech catalysts (Immunic/Imunon Phase 3 data E2026), financing wins (ImmunityBio $75M non-dilutive), but red flags in dilution/negative equity (11/29). Portfolio implications: Favor capital return plays and turnaround bios over loss-making microcaps; tech signals limited but Snowflake guidance reaffirm stable. Sector patterns signal caution on expense surges outpacing sales in growth firms.

18 high priority 11 medium 29 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 31, 2026

Across 35 NASDAQ-100 related SEC filings from March 31, 2026, mixed sentiment dominates (14/35 filings), reflecting narrowed losses in 8 companies (e.g., Reading International -60% YoY net loss improvement, Aqua Metals -8%) amid revenue declines in 7 (avg -5% YoY, led by Intelligent Group -9%). Strong outliers include Commercial Metals +21.6% YoY Q2 sales to $2.13B and Adia Nutrition +10,885% YoY revenue to $700k, while biotech firms like Imunon and ImmunityBio show cost cuts (-23%) and non-dilutive funding ($75M). Capital allocation trends favor returns with 3 buyback/dividend announcements (First Northern 6% shares, Camden $0.42/share), debt reductions (Reading -$32M), and M&A (Richmond Mutual $85M deal). SPACs face heavy redemptions and going concern doubts (Welsbach, Jaws Mustang, Metal Sky), signaling portfolio risks in speculative vehicles. Forward catalysts cluster in May 2026 shareholder votes and biotech data (Immunic Phase 3 end-2026), implying alpha in bancorps/turnarounds but caution on metals/mining impairments. Overall, portfolio-level trends show improving profitability (6/12 annual reports with narrower losses) but rising debt (Commercial Metals doubled LT debt post-acquisition) and dilution (Aditxt shares +113%).

21 high priority 14 medium 35 total filings